SR1664
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522455

CAS#: 1338259-05-4

Description: SR1664 is a potent and selective PPARγ inhibitor with potential antidiabetic activity. SR1664 binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPARγ agonist activity.


Chemical Structure

img
SR1664
CAS# 1338259-05-4

Theoretical Analysis

MedKoo Cat#: 522455
Name: SR1664
CAS#: 1338259-05-4
Chemical Formula: C33H29N3O5
Exact Mass: 547.21072
Molecular Weight: 547.61
Elemental Analysis: C, 72.38; H, 5.34; N, 7.67; O, 14.61

Size Price Shipping out time Quantity
5mg USD 285 2 Weeks
10mg USD 430 2 Weeks
25mg USD 855 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-02. Prices are subject to change without notice.

SR1664, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: SR1664; SR-1664; SR 1664.

IUPAC/Chemical Name: (S)-4'-((2,3-dimethyl-5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid

InChi Key: IIJDFXNUWZTHIM-NRFANRHFSA-N

InChi Code: InChI=1S/C33H29N3O5/c1-20-22(3)35(19-23-8-10-25(11-9-23)28-6-4-5-7-29(28)33(38)39)31-17-14-26(18-30(20)31)32(37)34-21(2)24-12-15-27(16-13-24)36(40)41/h4-18,21H,19H2,1-3H3,(H,34,37)(H,38,39)/t21-/m0/s1

SMILES Code: O=C(C1=CC=CC=C1C2=CC=C(CN3C(C)=C(C)C4=C3C=CC(C(N[C@H](C5=CC=C([N+]([O-])=O)C=C5)C)=O)=C4)C=C2)O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 547.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Asteian A, Blayo AL, He Y, Koenig M, Shin Y, Kuruvilla DS, Corzo CA, Cameron MD, Lin L, Ruiz C, Khan S, Kumar N, Busby S, Marciano DP, Garcia-Ordonez RD, Griffin PR, Kamenecka TM. Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists. ACS Med Chem Lett. 2015 Aug 4;6(9):998-1003. doi: 10.1021/acsmedchemlett.5b00218. eCollection 2015 Sep 10. PubMed PMID: 26396687; PubMed Central PMCID: PMC4569877.

2: Milton FA, Cvoro A, Amato AA, Sieglaff DH, Filgueira CS, Arumanayagam AS, de Lima Mdo C, Pitta IR, de Assis Rocha Neves F, Webb P. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2015 Aug 28;464(3):718-23. doi: 10.1016/j.bbrc.2015.07.011. Epub 2015 Jul 10. PubMed PMID: 26168725.

3: Marciano DP, Kuruvilla DS, Boregowda SV, Asteian A, Hughes TS, Garcia-Ordonez R, Corzo CA, Khan TM, Novick SJ, Park H, Kojetin DJ, Phinney DG, Bruning JB, Kamenecka TM, Griffin PR. Pharmacological repression of PPARγ promotes osteogenesis. Nat Commun. 2015 Jun 12;6:7443. doi: 10.1038/ncomms8443. PubMed PMID: 26068133; PubMed Central PMCID: PMC4471882.

4: Choi JS, Choi SS, Kim ES, Seo YK, Seo JK, Kim EK, Suh PG, Choi JH. Flightless-1, a novel transcriptional modulator of PPARγ through competing with RXRα. Cell Signal. 2015 Mar;27(3):614-20. doi: 10.1016/j.cellsig.2014.11.035. Epub 2014 Dec 2. PubMed PMID: 25479590.

5: Choi SS, Kim ES, Koh M, Lee SJ, Lim D, Yang YR, Jang HJ, Seo KA, Min SH, Lee IH, Park SB, Suh PG, Choi JH. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity. J Biol Chem. 2014 Sep 19;289(38):26618-29. doi: 10.1074/jbc.M114.566794. Epub 2014 Aug 6. PubMed PMID: 25100724; PubMed Central PMCID: PMC4176243.

6: Norris AW, Sigmund CD. A second chance for a PPARγ targeted therapy? Circ Res. 2012 Jan 6;110(1):8-11. doi: 10.1161/RES.0b013e3182435d88. PubMed PMID: 22223206; PubMed Central PMCID: PMC3583552.

7: Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Schürer SC, Vidović D, Shulman GI, Spiegelman BM, Griffin PR. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature. 2011 Sep 4;477(7365):477-81. doi: 10.1038/nature10383. PubMed PMID: 21892191; PubMed Central PMCID: PMC3179551.